{"name":"Pacylex Pharmaceuticals","slug":"pacylex-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"Pacylex Pharmaceuticals is a biotechnology company focused on the development of novel therapies for cancer. The company has a pipeline of seven drug candidates, all in Phase 1 clinical trials, with a primary focus on oncology.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PCLX-001 - 20mg","genericName":"PCLX-001 - 20mg","slug":"pclx-001-20mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"PCLX-001 - 20mg","genericName":"PCLX-001 - 20mg","slug":"pclx-001-20mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPSlFhcVdwaFlONm5LenM3akJpY2hmc04zT3hMeWFVMm50ZTBMTWNZNlFWRFBUOUdJZ010blhQNkpKR1gzd2NwN0lDOXFRQlFQVmZZSW82aDRiYU94a3VaZDkxWWsxTWJGUEJlNnJWa1pGV2FEZkFLX3QyVWJJSDQ2ajgxZnVQY25wZnloZ3RBOVR4RGhSZ1REYjhHWGhzeTlmVjFmbEQ5b1ZSTktKQzltVDM0bHdBNm1DSEM2S1VSbEl0a0QybjUzZE5laFF2YTFqSkZNYlVrdXBKQm9lVjlZTTZiSDMwa3YzMUgwaHAxeV82LVNKZTFoZUI5ZG1NbThqUlE5bEFBUWJ6Rm5XcVV5Q2VWNl9NREdCN2lycUhOU2otUEh6NDBmSERtS3VPaENoMnI3M0tKRmxmTjg?oc=5","date":"2025-05-13","type":"trial","source":"GlobeNewswire","summary":"Metastatic Colorectal Cancer Clinical Trial Pipeline - GlobeNewswire","headline":"Metastatic Colorectal Cancer Clinical Trial Pipeline","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxOOEloNzBMUVo2VDlxYlpXM2NsZWh0Zmgyb0dZc2dWaXJNUm9adUtqNmdKaWVIWGZnbFJrdWE3bHhZeFlMYkZfc1lpb0N3TXVRQXExTUJaQUZFWFdOTlJOQjhsYkpBM2piWEhJazBwRlpKaUs2YzN0LWFyLW1OUFFSREpRM1IzbklTVkU0Y2RSUHB6TTdnNG0zUGZMVHNnWHhhVlZMRXdwNklETXVwY0tSQ2J3am82VmpRQ2dRX2d6WHh0cGg0TGR4ZEVTb1JGYXNKX2I4S0xBcDFsSWRla1JmaXEzdHdGTVlPcXVXSXJWekRLdUNzQk1VS1YzMVVQVjE2eFZLQjB6Y2JhWFZTbWZXN2l5OFRlOEYxZ3o2ZHFHMkJuMUdZM0ltX3NJRTJSNWVZTWUybThENGFlSWh4ZWc?oc=5","date":"2025-04-23","type":"pipeline","source":"PR Newswire","summary":"Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakthrough Therapies Gain Traction | DelveInsight - PR Newswire","headline":"Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQVWJrbUtIRjUyRTh6ZTJHUHpjd0YzTnhkcVZSRFpzajFyaXVPZmxXd2xwYWJjUnVjVVVNb0dMOEEybThSSEsxbnlSeXZVcGJyalc5Rmc5RXJtUGIteDl4SWhvZ3ZWRWxMZG1kaENlazd5VE1oMTJLNGw5TTVZMXVkYVdjSEdGMG9ReHdmN1AweU02NTdUYkE?oc=5","date":"2025-03-17","type":"trial","source":"Yahoo Finance","summary":"Pacylex Pharmaceuticals Announces the First Acute Myeloid Leukemia (AML) Patient Dosed with Zelenirstat In a New Phase 1/2 Clinical Trial - Yahoo Finance","headline":"Pacylex Pharmaceuticals Announces the First Acute Myeloid Leukemia (AML) Patient Dosed with Zelenirstat In a New Phase 1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOZ0l2TWpXcVVoVE5vLW5uN2VZOVkzeTZ6QWVQVTZjcmIxTzA2Q0kzVzFnaFBFWllLQ05wYS01YmZ0UllxUmVPRE5IalN1NU52eG85ckpYY2JKWEdkYjdYYXZwTkNRTk41WjB6ZERSQWl4eVV0VlZBaUNHeTlRZ0YydEFUU0QwZzNWTnQzNEx3ektLaDNLTlBsX1I0aExyampHUjNPQ1BNaEw1SmFHRGpMNnM0elg?oc=5","date":"2024-05-24","type":"trial","source":"BioSpace","summary":"Pacylex Pharmaceuticals Reports Zelenirstat Phase 1 Safety and Efficacy Data at ASCO 2024 - BioSpace","headline":"Pacylex Pharmaceuticals Reports Zelenirstat Phase 1 Safety and Efficacy Data at ASCO 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5ENHFJaVdnVWkyNDJ4WWpVb3NOSzU2YjZsdW5JSEEydWFYd21yV1BHRUpwM2JPOWlZMXlwMTc0RTYtZE9MSXAyYWpSTFBjQkpJRnE4SkxSRGFHcXRfcUQwMzRKRkN1VzhE?oc=5","date":"2024-02-15","type":"pipeline","source":"Wiley Online Library","summary":"Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups - Wiley Online Library","headline":"Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxOTjA5dWhXMURfS1dHR2lWdmtULTlzUWZhM1Q1MW5VUHREeXNNclVib1plRDdtRHl3WVc2N1RXODFoQTRsTWJPMW5ZLWxlaDlRSTZ5WWlmNWF1VmJudkpTcmZoRFFqMzV4ZTNUSmF0ZUkxVml4Z1RpaW5rN2VVY2RoWWJIUFcxMXhCTXJ5VXFpLXhvUzJjbHl6VVBZTlpwNVdQcWRxclRkMEk2anZZVUVSVXhKUnpUZ0pVdjRVWFZnYUNqTnF2dVlYYmVYU01YbVk4TU4wY0xwRV9LOTNmY0JKdkY5WTU?oc=5","date":"2023-10-03","type":"pipeline","source":"TMX Newsfile","summary":"Pacylex Pharmaceuticals's Zelenirstat Shows Potent in vitro Radiosensitization in Human Glioblastoma Models - TMX Newsfile","headline":"Pacylex Pharmaceuticals's Zelenirstat Shows Potent in vitro Radiosensitization in Human Glioblastoma Models","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-05-31","type":"trial","source":"GlobeNewswire","summary":"B-Cell Lymphoma Clinical Trial Pipeline Insights: - GlobeNewswire","headline":"B-Cell Lymphoma Clinical Trial Pipeline Insights:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNeVN5b0liN28wcXdTdzEyNjZ6NWpQelR1dURjeVJCQ2s0WjZkWGpwdUtmb3hKRFZ5OExsNGItaFVNRi1lcFpzMTFFZHJRN1dCX0o3R0w3bkFvdU90cWprOUpQS0FuU1EtTi0xWGxfUWlFaDI5a3c2WVplbHpsRkUtVk5XcmIyaU96SEJZYTNtbVo?oc=5","date":"2023-04-10","type":"regulatory","source":"Timmerman Report","summary":"In Support of FDA’s Authority to Regulate Medicines - Timmerman Report","headline":"In Support of FDA’s Authority to Regulate Medicines","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}